The vaccine combines the antigenic components of GSK’s two well-established meningococcal vaccines, BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal [Groups A, C, Y, and W-135 ...

GSK’s MenABCWY vaccine combines the antigenic components of the Company’s two well-established meningococcal vaccines—BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal ...

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, is currently under review in the United States. A decision from the FDA is expected on Feb. 14, 2025.

Importantly, Penmenvy integrates the antigenic components of GSK’s two widely used meningococcal vaccines, Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A, C, Y, and ...

GSK has received the Food and Drug Administration’s permission for Penmenvy (meningococcal groups A, B, C, W and Y vaccine) for use in individuals aged 10 through 25 years.

Two new vaccines are cleared to hit the market following the U.S. FDA’s approval over the weekend for Vimkunya, a chikungunya vaccine from Bavarian Nordic A/S, and Penmenvy, a meningococcal vaccine ...

Pretty Hurts builds off the 2023 GSK and Lifetime co-branded short film, “I Never Thought to Ask: A Mom's Quest for Answers,” which also brought awareness to meningitis B and vaccination.

In addition to the new dosing schedule for MenB-4C, the ACIP discussed potential recommendations for GSK’s pentavalent vaccine, which is under review by the FDA.

The new recommendations align the dosing and intervals for GSK's vaccine both with recent label changes and to that of Pfizer's meningococcal group B vaccine, MenB-FHbp (Trumenba).